We’re currently experiencing extremely high call volumes. We’re very sorry for any inconvenience this might cause.

If you need help with your account, please visit our Help Centre, or email us and we’ll get back to you as soon as we can. For more information and tips on managing your account online please visit www.hl.co.uk/coronavirus

We’re experiencing high call volumes, please check FAQs before calling.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

Biodelivery Sciences International (BDSI) Common Stock US$0.001

Sell:$3.79 Buy:$3.80 Change: $0.06 (1.61%)
NASDAQ:0.95%
Market closed |  Prices as at close on 31 March 2020 | Switch to live prices |
Sell:$3.79
Buy:$3.80
Change: $0.06 (1.61%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 31 March 2020 | Switch to live prices |
Sell:$3.79
Buy:$3.80
Change: $0.06 (1.61%)
Market closed |  Prices as at close on 31 March 2020 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Contact details

Address:
4131 Parklake Ave Ste 225
RALEIGH
27612-2390
United States
Telephone:
+1 (919) 5829050
Website:
https://www.bdsi.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BDSI
ISIN:
US09060J1060
Market cap:
$359.37 million
Shares in issue:
96.34 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Peter Greenleaf
    Independent Chairman of the Board
  • Scott Plesha
    President, Chief Commercial Officer
  • Herm Cukier
    Chief Executive Officer, Director
  • Terry Coelho
    Chief Financial Officer
  • Joseph Lockhart
    Senior Vice President - Operations
  • Kevin Ostrander
    Senior Vice President - Business Development
  • James Vollins
    Chief Compliance Officer, General Counsel, Corporate Secretary
  • Thomas Smith
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.